Phosphorylation of ERa at serine 118 in primary breast cancer and in tamoxifen- resistant tumours is indicative of a complex role for ERa phosphorylation in breast cancer progression

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Glycogen Synthase Kinase-3 Interacts with and Phosphorylates Estrogen Receptor α and Is Involved in the Regulation of Receptor Activity*

  2005cited by this paper
• Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors.

  2005cited by this paper
• Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.

  2005cited by this paper
• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  2005cited by this paper
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005influential reference
• Protein phosphatase 5 is a negative regulator of estrogen receptor-mediated transcription.

  2004cited by this paper
• Phospho-serine-118 estrogen receptor-alpha detection in human breast tumors in vivo.

  2004cited by this paper
• Mechanisms of tamoxifen resistance.

  2004cited by this paper
• Phospho-Serine-118 Estrogen Receptor-α Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen

  2004cited by this paper
• Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

  2004cited by this paper
• Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.

  2003cited by this paper
• Overview of the main outcomes in breast-cancer prevention trials.

  2003cited by this paper
• Aromatase inhibitors for breast cancer: lessons from the laboratory

  2003cited by this paper
• Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.

  2003cited by this paper
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*

  2003cited by this paper
• Regulation of Estrogen Receptor α-mediated Transcription by a Direct Interaction with Protein Phosphatase 2A*

  2003cited by this paper
• Anti-oestrogenic prevention of breast cancer — the make or break point

  2002cited by this paper
• Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression.

  2002cited by this paper
• Endocrine-responsive breast cancer and strategies for combating resistance

  2002cited by this paper
• Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera

  2002influential reference
• The role of mitogen-activated protein (MAP) kinase in breast cancer.

  2002cited by this paper
• Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

  2001cited by this paper
• Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer

  2001influential reference
• Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

  2001cited by this paper
• Nuclear receptors and lipid physiology: opening the X-files.

  2001cited by this paper
• Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7.

  2000cited by this paper
• Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach.

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000influential reference
• Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.

  1998influential reference
• Estradiol-induced Phosphorylation of Serine 118 in the Estrogen Receptor Is Independent of p42/p44 Mitogen-activated Protein Kinase*

  1998influential reference
• Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.

  1998cited by this paper
• Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells.

  1997cited by this paper
• Hyperexpression of mitogen-activated protein kinase in human breast cancer.

  1997influential reference
• Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

  1996influential reference
• Microsatellite instability in early sporadic breast cancer.

  1996cited by this paper
• Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.

  1996influential reference
• Oestrogen receptor: a stable phenotype in breast cancer.

  1996cited by this paper
• Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

  1995cited by this paper
• Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor.

  1995cited by this paper
• Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase

  1995cited by this paper
• Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines.

  1995cited by this paper
• A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples.

  1995cited by this paper
• Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

  1994cited by this paper
• Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity.

  1994cited by this paper
• Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction.

  1994cited by this paper
• Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line.

  1993cited by this paper
• Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region.

  1993cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1988cited by this paper
• Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

  1985cited by this paper
• human breast cancer: functional analysis and clinical

  year unknowncited by this paper

• IL6 induces TAM resistance via kinase-specific phosphorylation of ERα in OVCA cells.

  2015cites this paper
• Clinical significance of estrogen receptor phosphorylation.

  2011cites this paper
• A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.

  2009cites this paper
• Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity

  2008influential citation
• Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients

  2007cites this paper